Details of the Drug

General Information of Drug (ID: DM0YWJC)

Drug Name

Safinamide

Synonyms

133865-89-1; Xadago; (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide; Fce-26743; UNII-90ENL74SIG; (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide; EMD 1195686; 90ENL74SIG; CHEMBL396778; EMD-1195686; AK-77847; 2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide; CHEMBL48582; Safinamide [USAN:INN]; 2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide; AC1L2ZLK; Safinamide (USAN/INN); (S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide; EC 603-772-2; SCHEMBL69350; Fce 26743; ON 019190.Na

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]
Idiopathic parkinson disease	8A00.0Z	Phase 3	[2], [3]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

302.34

Topological Polar Surface Area (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The apparent oral clearance of drug is 17.53 +/- 2.71 mL/h/kg [4]
Elimination: The elimination of drug is 76% via renal and 1.5% via feces [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 22 hours [5]
Metabolism: The drug is metabolized via the amidases [6]
Vd: The volume of distribution (Vd) of drug is 1.8 L/kg [4]

Chemical Identifiers

Formula: C17H19FN2O2
IUPAC Name: (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
Canonical SMILES: C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
InChI: InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
InChIKey: NEMGRZFTLSKBAP-LBPRGKRZSA-N

Cross-matching ID

PubChem CID: 131682
ChEBI ID: CHEBI:134718
CAS Number: 133865-89-1
DrugBank ID: DB06654
TTD ID: D0TV6I
VARIDT ID: DR00042
ACDINA ID: D00612

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[7], [8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Monoamine oxidase type B (MAO-B)	DTT	MAOB	2.65E-02	1.12E-02	0.07

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Safinamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Safinamide and Levalbuterol.	Asthma [CA23]	[18]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Safinamide due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[19]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Safinamide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Vilanterol	DMF5EK1	Moderate	Additive hypertensive effects by the combination of Safinamide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Safinamide and Levomilnacipran.	Chronic pain [MG30]	[21]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Safinamide and Vilazodone.	Depression [6A70-6A7Z]	[21]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Safinamide and Vortioxetine.	Depression [6A70-6A7Z]	[21]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Safinamide and Desvenlafaxine.	Depression [6A70-6A7Z]	[21]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Safinamide and Esketamine.	Depression [6A70-6A7Z]	[22]
Deutetrabenazine	DMUPFLI	Major	Additive hypertensive effects by the combination of Safinamide and Deutetrabenazine.	Dystonic disorder [8A02]	[23]
Tetrahydrozoline	DMT57WC	Moderate	Decreased metabolism of Safinamide caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme.	Herpes simplex infection [1F00]	[24]
Aliskiren	DM1BV7W	Moderate	Additive hypotensive effects by the combination of Safinamide and Aliskiren.	Hypertension [BA00-BA04]	[25]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Safinamide and Levamlodipine.	Hypertension [BA00-BA04]	[25]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Safinamide and TAK-491.	Hypertension [BA00-BA04]	[25]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Safinamide due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[26]
Naphazoline	DMJFZDL	Moderate	Decreased metabolism of Safinamide caused by Naphazoline mediated inhibition of non-CYP450 enzyme.	Itching [1F28-1G07]	[24]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Safinamide due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[22]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Safinamide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[27]
Ubrogepant	DM749I3	Moderate	Decreased clearance of Safinamide due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[28]
Rimegepant	DMHOAUG	Moderate	Decreased clearance of Safinamide due to the transporter inhibition by Rimegepant.	Migraine [8A80]	[29]
Lasmiditan	DMXLVDT	Major	Additive serotonergic effects by the combination of Safinamide and Lasmiditan.	Migraine [8A80]	[21]
Ozanimod	DMT6AM2	Major	Decreased metabolism of Safinamide caused by Ozanimod mediated inhibition of non-CYP450 enzyme.	Multiple sclerosis [8A40]	[30]
Propylhexedrine	DMTBW2O	Moderate	Decreased metabolism of Safinamide caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme.	Obesity [5B80-5B81]	[24]
Selexipag	DMAHSU0	Moderate	Additive hypotensive effects by the combination of Safinamide and Selexipag.	Pulmonary hypertension [BB01]	[25]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Safinamide and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[31]
-----------


⏷ Show the Full List of 25 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Haematite red	E00236	14833	Colorant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Potassium aluminum disilicate	E00401	123904	Other agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Safinamide Mesylate 100 mg tablet	100 mg	Tablet	Oral
Safinamide Mesylate 50 mgl tablet	50 mgl	Tablet	Oral
Safinamide 100 mg tablet	100 mg	Oral Tablet	Oral
Safinamide 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8291).
3	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
4	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
8	Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
9	Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
10	Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
12	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
13	Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
14	Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
15	Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
16	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
17	Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
18	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
19	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
20	Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
21	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
22	Cerner Multum, Inc. "Australian Product Information.".
23	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
24	Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
25	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
26	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
27	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
28	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
29	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
30	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
31	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]